Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon May 09, 2024 5:12pm
183 Views
Post# 36032237

RE:Like I said, FUDsters working overtime

RE:Like I said, FUDsters working overtimeFrom the call, 
They were very clear.
details of both MBc & pancreatic phase 3 trials will be presented THIS QUARTER.
meaning within next 5-6 weeks.
The fda meeting has been granted. While they did not give exact day or time. They said has been granted & will be in this quarter.
since, they can not afford a phase 3 without a partner, logical progression?
1. details from FDA.
2.:partership with Roche/ pfuzer or other to describe start of phase 3 mbc
soecisl note.
Once the FDA trial details are colated & released. The China partner will be able to start their phase three, ASAP.
triggering milestone payments.

last , very subtle, but very important.
They are looking to pre- design a MBc trial , with appropriate results leading to direct product approval.
on the pancrestic side?
They are aiming for & predict Pelareorep to be standard of care , for a very broad range of pancreatic cancers.
The call is recorded. I recommend people listen in for yourself.
dont take my word.
Obviously no partership yet.
however , all indications point to that being announced soon after the FDA meeting results are made public.

<< Previous
Bullboard Posts
Next >>